2025 NRDL outlook: A fork in the road
.t-1 { border-collapse: collapse; } .t-2 { border-collapse: collapse; } .t-1 td { border: 1px solid grey; padding: 5px; } .t-2 td { border: 1px solid grey; padding: 5px; } .t-2tip { padding: 5px; background-color: #728e9e; border-radius: 5px; color: white; font-weight: bold; position: relative; } .t-2tip::before { content: ''; display: block; height: 15px; width: 30px; position: absolute; top: -15px; left: 33%; border-left: 15px solid transparent; border-right: 15px solid transparent; border-bottom: 15px solid #728e9e; }
2025 NRDL features a record number of longlist candidates for NRDL new listing and renewals, and the latest debut of the C-list as an alternative for high-value high-cost therapies, heralding intense competition and interesting dynamics at the same time.
The 2025 National Reimbursement Drug List (NRDL) annual update has been unfolding as planned, with the first-round…
